Correction: R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects (Translational Psychiatry, (2015), 5, 9, (e632), 10.1038/tp.2015.136);R-ketamine: A rapid-onset and sustained antidepressant without psychotomimetic side effects

Translational Psychiatry

Volumn 5, Issue , 2015, Pages

  Yang, C ^a   Shirayama, Y ^a,b   Zhang, J C ^a   Ren, Q ^a   Yao, W ^a   Ma, M ^a   Dong, C ^a   Hashimoto, K ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TEIKYO UNIVERSITY CHIBA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; ESKETAMINE; KETAMINE; R KETAMINE; UNCLASSIFIED DRUG; ANTIDEPRESSANT AGENT; PSYCHEDELIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; DENTATE GYRUS; DEPRESSION; DRUG ABUSE; FORCED SWIM TEST; HIPPOCAMPAL CA3 REGION; HIPPOCAMPUS; LEARNED HELPLESSNESS; LOCOMOTION; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; NUCLEUS ACCUMBENS SHELL; PLACE PREFERENCE; PREFRONTAL CORTEX; PREPULSE INHIBITION; PYRAMIDAL NERVE CELL; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOCIAL STRESS; STEREOISOMERISM; SUCROSE PREFERENCE TEST; SYNAPTOGENESIS; TAIL SUSPENSION TEST; ANALYSIS OF VARIANCE; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DRUG EFFECTS; RAT; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN-DERIVED NEUROTROPHIC FACTOR; HALLUCINOGENS; KETAMINE; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84940855007     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/s41398-020-00983-3     Document Type: Erratum

References (63)

1. World Health Organization (WHO) Depression. Fact sheet No. 369 2012. Available at http://www.who.int/mediacentre/factsheets/fs369/en/index.html; last accessed on 28 July, 2015.
2. Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 2015; 16: 7796-7801.
3. Monteggia LM, Zarate C Jr. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 2015; 30: 139-143.
4. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharma-cotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 1999; 7: 125-143.
5. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009; 61: 105-123.
6. Machado-Vieira R, Ibrahim L, Henter ID, Zarate CA Jr. Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav 2012; 100: 678-687.
7. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuro-pharmacology 2012; 62: 63-77.
8. Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 2013; 263: 367-377.
9. Ohgi Y, Futamura T, Hashimoto K. Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 2015; 15: 206-221.
10. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010; 113: 678-684.
11. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013; 73: 1133-1141.
12. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47: 351-354.
13. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63: 856-864.
14. Price RB, Nock MK, Charney DS, Mathew SJ. Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry 2009; 66: 522-526.
15. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 2010; 67: 793-802.
16. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012; 71: 939-946.
17. Diazgranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA et al. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 2010; 71: 1605-1611.
18. Price RB, Iosifescu DV, Murrough JW, Chang LC, Al Jurdi RK, Iqbal SZ et al. Effects of ketamine on explicit and implicit suicidal cognition: a randomized controlled trial in treatment-resistant depression. Depress Anxiety 2014; 31: 335-343.
19. Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: a systematic review of the literature. Drugs R D 2015; 15: 37-43.
20. Fond G, Loundou A, Rabu C, Macgregor A, Lançon C, Brittner M et al. Ketamine administration in depressive disorders: a systematic review and meta-analysis. Psychopharmacology (Berl) 2014; 231: 3663-3676.
21. McGirr A, Berlim MT, Bond DJ, Fleck MP, Yatham LN, Lam RW. A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes. Psychol Med 2015; 45: 693-704.
22. Coyle CM, Laws KR. The use of ketamine as an antidepressant: a systematic review and meta-analysis. Hum Psychopharmacol 2015; 30: 152-163.
23. Kohrs R, Durieux ME. Ketamine: teaching an old drug new tricks. Anesth Analg 1998; 87: 1186-1193.
24. Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991; 148: 1301-1308.
25. Zhang JC, Li SX, Hashimoto K. R (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav 2014; 116: 137-141.
26. Hashimoto K. The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 2014; 12: 72-73.
27. Yang C, Hashimoto K. Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology (Berl) 2014; 231: 2041-2042.
28. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry 2006; 59: 1116-1127.
29. Nestler EJ, Carlezon WA Jr. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-1159.
30. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007; 87: 873-904.
31. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 2011; 475: 91-95.
32. Duman RS, Aghajanian GK. Synaptic dysfunction in depression: potential therapeutic targets. Science 2012; 338: 68-72.
33. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 2014; 18: pyu033.
34. Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C et al. Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 2015; 18: pyu077.
35. Jiang B, Wang F, Yang S, Fang P, Deng ZF, Xiao JL et al. SKF83959 produces antidepressant effects in a chronic social defeat stress model of depression through BDNF-TrkB pathway. Int J Neuropsychopharmacol 2015; 18: 1-13.
36. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K. Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol 2015; 18: pyu121.
37. Li SX, Fujita Y, Zhang JC, Ren Q, Ishima T, Wu J et al. Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure. Neurobiol Dis 2014; 62: 124-134.
38. Carorla M, Prémont J, Mann A, Girard N, Kellendonk C, Rognan D. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J Clin Invest 2011; 121: 1846-1857.
39. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 2013; 8: e56053.
40. Ren Q, Zhang JC, Ma M, Fujita Y, Wu J, Hashimoto K. 7, 8-Dihydroxyflavone, a TrkB agonist, attenuates behavioral abnormalities and neurotoxicity in mice after administration of methamphetamine. Psychopharmacology (Berl) 2014; 231: 159-166.
41. Golden SA, Covington HE III, Berton O, Russo SJ. A standard protocol for repeated social defeat stress in mice. Nat Protoc 2011; 6: 1183-1191.
42. Zhao T, Huang GB, Muna SS, Bagalkot TR, Jin HM, Chae HJ et al. Effects of chronic social defeat stress on behavior and choline acetyltransferase, 78-kDa glucose-regulated protein, and CCAAT/enhancer-binding protein (C/EBP) homologous protein in adult mice. Psychopharmacology (Berl) 2013; 228: 217-230.
43. Shirayama Y, Muneoka K, Fukumoto M, Tadokoro S, Fukami G, Hashimoto K et al. Infusions of allopregnanolone into the hippocampus and amygdala, but not into the nucleus accumbens and medial prefrontal cortex, produce antidepressant effects on the learned helplessness rats. Hippocampus 2011; 21: 1105-1113.
44. Muneoka K, Shirayama Y, Horio M, Iyo M, Hashimoto K. Differential levels of brain amino acids in rat models presenting learned helplessness or non-learned helplessness. Psychopharmacology (Berl) 2013; 229: 63-71.
45. Hashimoto K, Fujita Y, Horio M, Kunitachi S, Iyo M, Ferraris D et al. Co-administration of a D-amino acid oxidase inhibitor potentiates the efficacy of D-serine in attenuating prepulse inhibition deficits after administration of dizo-cilpine. Biol Psychiatry 2009; 65: 1103-1106.
46. Matsuura A, Fujita Y, Iyo M, Hashimoto K. Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phency-clidine. Acta Neuropsychiatr 2015; 27: 159-167.
47. Fujita Y, Kunitachi S, Iyo M, Hashimoto K. The antibiotic minocycline prevents methamphetamine-induced rewarding effects in mice. Pharmacol Biochem Behav 2012; 101: 303-306.
48. Shirai Y, Fujita Y, Hashimoto R, Ohi K, Yamamori H, Yasuda H et al. Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLoS One 2015; 10: e0127244.
49. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 2008; 63: 349-352.
50. Morgan CJ, Curran HV. Independent Scientist Committee on Drugs Ketamine use: a review. Addiction 2012; 107: 27-38.
51. Gonzalez-Burgos G, Cho RY, Lewis DA. Alterations in cortical network oscillations and parvalbumin neurons in schizophrenia. Biol Psychiatry 2015; 77: 1031-1040.
52. Cabungcal JH, Steullet P, Kraftsik R, Cuenod M, Do KQ. Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by N-acetylcysteine. Biol Psychiatry 2013; 73: 574-582.
53. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron 2002; 34: 13-25.
54. Hashimoto K, Shimizu E, Iyo M. Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 2004; 45: 104-114.
55. Hashimoto K. Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 2010; 64: 341-357.
56. Hashimoto K. Sigma-1 receptor chaperone and brain-derived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 2013; 100: 15-29.
57. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 2011; 69: 754-761.
58. Liu RJ, Ota KT, Dutheil S, Duman RS, Aghajanian GK. Ketamine strengthens CRF-activated amygdala inputs to basal dendrites in mPFC layer V pyramidal cells in the prelimbic but not infralimbic subregion, a key suppressor of stress response. Neuropsychopharmacology 2015; 40: 2066-2075.
59. Sato Y, Kobayashi E, Hakamata Y, Kobahashi M, Wainai T, Murayama T et al. Chronopharmacological studies of ketamine in normal and NMDA epsilon1 receptor knockout mice. Br J Anaesth 2004; 92: 859-864.
60. Fuchikami M, Thomas A, Liu R, Wohleb ES, Land BB, DiLeone RJ et al. Optogenetic stimulation of infralimbic PFC reproduces ketamine's rapid and sustained anti-depressant actions. Proc Natl Acad Sci USA 2015; 112: 8106-8111.
61. Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 1997; 333: 99-104.
62. Persson J, Hasselström J, Maurset A, Oye I, Svensson JO, Almqvist O et al. Pharma-cokinetics and non-analgesic effects of S- and R-ketamines in healthy volunteers with normal and reduced metabolic capacity. Eur J Clin Pharmacol 2002; 57: 869-875.
63. Vollenweider FX, Leenders KL, Oye I, Hell D, Angst J. Differential psychopathology and patterns of cerebral glucose utilization produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET). Eur Neuropsycho-pharmacol 1997; 7: 25-38.